NCT04813640

Eye Length Signal With Myopia Control

Status unknown NA Last updated 7 May 2021

What this trial tests

NA trial testing Spectacles in Myopia in 80 participants. Status unknown.

Timeline

5 February 2021

Primary endpoint
31 October 2021

31 October 2021

Quick facts

Lead sponsor	Brien Holden Vision Institute
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	80
Start date	5 February 2021
Primary completion	31 October 2021
Estimated completion	31 October 2021
Sites	1 location across Vietnam

Drugs / interventions tested

• Spectacles

Conditions studied

• Myopia — all drugs for Myopia →

Sponsor

Brien Holden Vision Institute

Who can join

Adults 7 to 14, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Myopia, considered as a global epidemic, is rapidly rising in prevalence especially in east Asian countries. Younger ages are associated with greater annual progression and thus early onset myopia is likely to result in higher levels of final net myopia.\[1\] Myopia, especially high myopia (more than -6.00D) is associated vision threatening complications such as cataract, glaucoma, choroidal thinning, vitreous liquefaction, myopic maculopathy, retinal detachment etc. Furthermore, myopia can affect the quality of life of an individual through restriction of employment in certain fields such as aviation. Myopia also imposes economic burden through the recurring cost of vision correction such as spectacles, contact lenses and specialist consultation fee. It is therefore important to develop novel optical and pharmaceutical strategies that can control or slow the progression of myopia.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Interventions for myopia control in children: a living systematic review and network meta-analysis.
   Lawrenson JG, Shah R, Huntjens B, Downie LE, et al · · 2023 · cited 117× · PMID 36809645 · DOI 10.1002/14651858.cd014758.pub2
2. Human retinal secretome: A cross-link between mesenchymal and retinal cells.
   Donato L, Scimone C, Alibrandi S, Scalinci SZ, et al · · 2023 · cited 6× · PMID 37545752 · DOI 10.4252/wjsc.v15.i7.665